Immunovaccine to Host Investor Event on April 10, 2018 in New York City
The event will feature an overview of Immunovaccine’s novel approach to targeted T cell therapy. Presentations by outside experts and
Details for the event are as follows:
The agenda will include:
Fred Ors, Chief Executive Officer,
Defining a New Approach to Targeted T Cell Therapy
Elucidating a Unique Mechanism of Action Using In Vivo MRI Tracking
Testing Various Immune Modulators for Neoepitope-mediated Cancer Immunotherapy
Pramod K. Srivastava, PhD, MD, Professor of Medicine and Immunology, Eversource Energy Chair in Experimental Oncology, Director,
T Cell Therapies for Cancer in Clinical Practice: Are We on
If you are a member of the investment community and would like to attend, please send an email to firstname.lastname@example.org to receive additional information.
A live broadcast of the event will be made available on the Investors section of the
Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals.
Contacts for Immunovaccine:
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E: email@example.com
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: Plabbe@imvaccine.com
O: (415) 513-1284
T: (415) 515-4572 E: firstname.lastname@example.org
Source: Immunovaccine Inc.